

Palmoplantar Pustulosis- Pipeline Insight, 2021

<https://marketpublishers.com/r/P88FB45F0AC5EN.html>

Date: February 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: P88FB45F0AC5EN

Abstracts

This report can be delivered to the clients within 48-72 Hours

DelveInsight's, "Palmoplantar Pustulosis – Pipeline Insight, 2021," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Palmoplantar Pustulosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Palmoplantar Pustulosis Understanding

Palmoplantar Pustulosis: Overview

Palmoplantar pustulosis (PPP) is a rare, recurrent inflammatory disorder. Affected individuals develop small to large sterile blisters filled with a yellow turbid liquid (pustules) on the palms of the hands and/or soles of the feet. The pustules may be painful and cause a burning feeling. The exact cause of PPP is not known. Researchers have determined that possible causes include smoking, bacterial infections (acute or chronic tonsillitis, dental infection, chronic sinusitis), contact allergies (mainly metals) and certain medications. The most common symptoms include: red and tender skin, blisters and pustules (fluid-filled bumps) on the palms of the hands and the soles of the feet, itchiness, pain, skin cracks, scaly skin, dry and thick skin. There's no cure for palmoplantar pustulosis. Treatment may help to manage the symptoms.

“Palmoplar Pustulosis - Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Palmoplar Pustulosis pipeline landscape is provided which includes the disease overview and Palmoplar Pustulosis treatment guidelines. The assessment part of the report embraces, in depth Palmoplar Pustulosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Palmoplar Pustulosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Palmoplar Pustulosis R&D. The therapies under development are focused on novel approaches to treat/improve Palmoplar Pustulosis.

Palmoplar Pustulosis Emerging Drugs Chapters

This segment of the Palmoplar Pustulosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Palmoplar Pustulosis Emerging Drugs

KHK4827 (Brodalumab): Kyowa Kirin Co. Ltd.

Brodalumab is a Human monoclonal antibody designed for the treatment of inflammatory diseases. Brodalumab binds to the interleukin-17 receptor and so prevents interleukin 17 (IL-17) from activating the receptor. It is currently in Phase III stage of development for palmoplar pustulosis.

Imsidolimab: AnaptysBio, INC.

Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of

the interleukin-36-receptor, or IL-36R, which we are initially developing as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis (GPP), palmoplantar pustulosis (PPP). The study is a Phase II, randomized, placebo-controlled, double-blind, multiple dose study to evaluate the efficacy and safety, and PK of ANB019 in subjects with Palmoplantar Pustulosis.

Further product details are provided in the report.....

Palmoplantar Pustulosis: Therapeutic Assessment

This segment of the report provides insights about the different Palmoplantar Pustulosis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Palmoplantar Pustulosis

There are approx. 8+ key companies which are developing the therapies for Palmoplantar Pustulosis. The companies which have their Palmoplantar Pustulosis drug candidates in the most advanced stage, i.e. phase III include, Kyowa Kirin Co., Ltd.

Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

Route of Administration

Palmoplantar Pustulosis pipeline report provides the therapeutic assessment of the

pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Palmoplantar Pustulosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Palmoplantar Pustulosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Palmopantar Pustulosis drugs.

Palmopantar Pustulosis Report Insights

Palmopantar Pustulosis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Palmopantar Pustulosis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Palmopantar Pustulosis drugs?

How many Palmopantar Pustulosis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Palmoplantar Pustulosis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Palmoplantar Pustulosis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Palmoplantar Pustulosis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Kyowa Kirin Co., Ltd.

Aristea Therapeutics Inc.

AnaptysBio, Inc.

Boehringer Ingelheim

Janssen Biotech

Key Products

BI655310

RIST4721-201

KHK4827

ANB019

Guselkumab

Contents

Introduction

Executive Summary

Palmoplantar Pustulosis: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Palmoplantar Pustulosis – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Palmoplantar Pustulosis companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Palmoplantar Pustulosis Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

KHK4827 (Brodalumab): Kyowa Kirin Co. Ltd.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Imsidolimab: AnaptysBio, Inc.

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

Drug Name: Company Name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Palmopltantar Pustulosis Key Companies

Palmopltantar Pustulosis Key Products

Palmopltantar Pustulosis- Unmet Needs

Palmopltantar Pustulosis- Market Drivers and Barriers

Palmopltantar Pustulosis- Future Perspectives and Conclusion

Palmopltantar Pustulosis Analyst Views

Palmopltantar Pustulosis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Palmoplantar Pustulosis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Palmoplantar Pustulosis

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Palmopltantar Pustulosis- Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/P88FB45F0AC5EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P88FB45F0AC5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970